Ionis Pharmaceuticals, Inc. (IONS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
52/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseIONS / S&P 5.59% / 15.20% |
LoseIONS / S&P -7.41% / 15.00% |
WinIONS / S&P 89.13% / 50.40% |
| 2026-Q11/3 |
LoseIONS / S&P -5.08% / -4.33% |
WinIONS / S&P 47.53% / 11.30% |
LoseIONS / S&P -30.10% / 27.70% |
| 2025-Q42/3 |
WinIONS / S&P 20.93% / 2.65% |
WinIONS / S&P 33.83% / 9.00% |
LoseIONS / S&P -19.08% / 13.40% |
| 2025-Q32/3 |
WinIONS / S&P 65.58% / 8.12% |
WinIONS / S&P 20.41% / 4.61% |
LoseIONS / S&P -30.74% / 13.45% |
| 2025-Q22/3 |
WinIONS / S&P 30.96% / 10.94% |
WinIONS / S&P 16.05% / 4.83% |
LoseIONS / S&P -26.98% / 10.63% |
| 2025-Q11/3 |
LoseIONS / S&P -13.70% / -4.27% |
LoseIONS / S&P -7.64% / 4.98% |
WinIONS / S&P 11.99% / 10.57% |
| 2024-Q41/3 |
LoseIONS / S&P -12.73% / 2.41% |
LoseIONS / S&P -10.48% / 5.25% |
WinIONS / S&P 18.75% / 6.15% |
| 2024-Q31/3 |
LoseIONS / S&P -15.95% / 5.89% |
WinIONS / S&P 30.57% / 5.89% |
LoseIONS / S&P -14.98% / 6.11% |
| 2024-Q23/3 |
WinIONS / S&P 9.94% / 4.28% |
WinIONS / S&P 29.00% / 5.38% |
WinIONS / S&P 16.13% / 5.12% |
| 2024-Q12/3 |
LoseIONS / S&P -14.31% / 10.56% |
WinIONS / S&P 34.84% / 5.71% |
WinIONS / S&P 15.58% / 5.59% |
| 2023-Q42/3 |
LoseIONS / S&P 11.53% / 11.69% |
WinIONS / S&P 34.10% / 6.81% |
WinIONS / S&P 34.74% / 7.78% |
| 2023-Q31/3 |
WinIONS / S&P 10.55% / -3.27% |
LoseIONS / S&P -29.75% / 7.52% |
LoseIONS / S&P -4200.00% / -5.03% |
| 2023-Q22/3 |
WinIONS / S&P 14.80% / 8.74% |
LoseIONS / S&P -25.71% / 9.50% |
WinIONS / S&P 1105.56% / -8.57% |
| 2023-Q11/3 |
LoseIONS / S&P -5.37% / 7.50% |
LoseIONS / S&P -31.49% / 10.77% |
WinIONS / S&P 23000.00% / -15.69% |
| 2022-Q41/3 |
LoseIONS / S&P -14.61% / 7.56% |
LoseIONS / S&P -27.53% / 11.88% |
WinIONS / S&P 900.00% / -17.99% |
| 2022-Q32/3 |
WinIONS / S&P 19.48% / -4.88% |
WinIONS / S&P 32.50% / 13.47% |
LoseIONS / S&P -101.62% / -1.41% |
| 2022-Q22/3 |
WinIONS / S&P -0.05% / -16.10% |
WinIONS / S&P 23.42% / 13.71% |
LoseIONS / S&P -95.42% / 11.04% |
| 2022-Q12/3 |
WinIONS / S&P 21.72% / -4.60% |
WinIONS / S&P 18.84% / 15.97% |
LoseIONS / S&P -99.72% / 42.23% |
| 2021-Q40/3 |
LoseIONS / S&P -9.27% / 11.03% |
LoseIONS / S&P 11.13% / 15.00% |
LoseIONS / S&P -94.03% / 96.40% |
| 2021-Q30/3 |
LoseIONS / S&P -15.92% / 0.58% |
LoseIONS / S&P -29.16% / 10.77% |
LoseIONS / S&P -1021.28% / 69.42% |
| 2021-Q20/3 |
LoseIONS / S&P -11.28% / 8.55% |
LoseIONS / S&P -26.88% / 6.58% |
LoseIONS / S&P -573.49% / 51.81% |
| 2021-Q10/3 |
LoseIONS / S&P -20.48% / 6.17% |
LoseIONS / S&P -26.21% / -1.06% |
LoseIONS / S&P -454.00% / 7.39% |
| 2020-Q41/3 |
WinIONS / S&P 19.16% / 12.15% |
LoseIONS / S&P -35.04% / -3.72% |
LoseIONS / S&P -267.37% / -33.42% |
| 2020-Q31/3 |
LoseIONS / S&P -19.52% / 8.93% |
WinIONS / S&P 13.60% / -2.04% |
LoseIONS / S&P -85.27% / -27.10% |
| 2020-Q22/3 |
WinIONS / S&P 24.70% / 20.54% |
WinIONS / S&P 17.78% / -0.46% |
LoseIONS / S&P -72.15% / -27.11% |
| 2020-Q11/3 |
LoseIONS / S&P -21.73% / -19.60% |
WinIONS / S&P 27.41% / 3.47% |
LoseIONS / S&P -62.96% / -14.75% |
| 2019-Q41/3 |
LoseIONS / S&P 0.83% / 9.07% |
WinIONS / S&P 87.20% / 5.36% |
LoseIONS / S&P -8.21% / 2.99% |
| 2019-Q31/3 |
LoseIONS / S&P -6.78% / 1.70% |
WinIONS / S&P 42.70% / 5.02% |
LoseIONS / S&P -1129.03% / 0.21% |
| 2019-Q21/3 |
LoseIONS / S&P -20.82% / 4.30% |
WinIONS / S&P 45.65% / 6.64% |
LoseIONS / S&P -1093.33% / 8.65% |
| 2019-Q12/3 |
WinIONS / S&P 50.15% / 13.65% |
WinIONS / S&P 38.63% / 8.12% |
LoseIONS / S&P -9100.00% / 14.29% |
| 2018-Q43/3 |
WinIONS / S&P 4.81% / -13.52% |
WinIONS / S&P 16.63% / 9.05% |
WinIONS / S&P 4040.00% / 18.23% |
| 2018-Q31/3 |
WinIONS / S&P 23.78% / 7.71% |
LoseIONS / S&P 7.97% / 10.21% |
LoseIONS / S&P -167.39% / 19.06% |
| 2018-Q20/3 |
LoseIONS / S&P -5.47% / 3.43% |
LoseIONS / S&P 4.33% / 9.03% |
LoseIONS / S&P -155.56% / 14.46% |
| 2018-Q11/3 |
LoseIONS / S&P -12.37% / -0.76% |
WinIONS / S&P 20.17% / 7.68% |
LoseIONS / S&P -133.33% / 12.46% |
| 2017-Q41/3 |
LoseIONS / S&P -0.79% / 6.64% |
WinIONS / S&P 37.93% / 7.03% |
LoseIONS / S&P -110.00% / 13.82% |
| 2017-Q31/3 |
LoseIONS / S&P -0.33% / 4.48% |
WinIONS / S&P 124.05% / 5.68% |
LoseIONS / S&P -130.07% / 17.57% |
| 2017-Q22/3 |
WinIONS / S&P 26.54% / 3.09% |
WinIONS / S&P 198.52% / 4.83% |
LoseIONS / S&P -128.57% / 17.74% |
| 2017-Q11/3 |
LoseIONS / S&P -15.95% / 6.07% |
WinIONS / S&P 75.08% / 3.67% |
LoseIONS / S&P -107.96% / 13.32% |
| 2016-Q42/3 |
WinIONS / S&P 30.54% / 3.82% |
WinIONS / S&P 31.40% / 2.09% |
LoseIONS / S&P IONS unavailable / 7.05% |
| 2016-Q31/3 |
WinIONS / S&P 57.32% / 3.85% |
LoseIONS / S&P -24.97% / 0.20% |
LoseIONS / S&P IONS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IONS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 46.41% | 20.78% |
| Annualized return | 46.41% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IONS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 54.99% | 83.14% |
| Annualized return | 9.16% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | IONS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 107.82% | 319.30% |
| Annualized return | 7.59% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |